Send to

Choose Destination
Cell Death Discov. 2018 Oct 3;5:46. doi: 10.1038/s41420-018-0106-x. eCollection 2018.

Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study.

Author information

1Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul, 01812 Republic of Korea.
2Department of Bio-Convergence Engineering, Korea University, Seoul, 02842 Republic of Korea.
3National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141 Republic of Korea.
4Radiation Non-Clinical Center, Korea Institute of Radiological and Medical Sciences, Seoul, 01812 Republic of Korea.
Contributed equally


Tumor treating fields (TTFs) are a newly developed cancer therapy technology using an alternating electric field that may be a possible candidate for overcoming the limitations of conventional treatment methods currently used in cancer treatment. Although clinical results using TTFs appear promising, concerns regarding side effects must be clarified to demonstrate the effectiveness of this treatment method. To investigate the side effects of TTF treatment, the damage to normal cell lines and normal tissue of a mouse model was compared with the damage to tumor cells and tumors in a mouse model after TTF treatment. No serious damage was found in the normal cells and normal tissues of the mouse model, suggesting that the side effects of TTF treatment may not be serious. Our evidence based on in vitro and in vivo experiments suggests that TTF may cause selective damage to cancer cells, further demonstrating the potential of TTF as an attractive alternative to conventional cancer treatment modalities.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center